Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) rose 9.8% on Wednesday . The stock traded as high as $13.90 and last traded at $13.86. Approximately 39,270 shares traded hands during trading, a decline of 80% from the average daily volume of 192,962 shares. The stock had previously closed at $12.62.
Analyst Upgrades and Downgrades
RAPP has been the subject of several recent analyst reports. JMP Securities restated a "market outperform" rating and set a $28.00 target price on shares of Rapport Therapeutics in a research note on Tuesday. Citizens Jmp initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They set a "mkt outperform" rating for the company.
Get Our Latest Stock Report on RAPP
Rapport Therapeutics Price Performance
The firm's fifty day moving average price is $11.25 and its 200-day moving average price is $12.08. The company has a market capitalization of $532.90 million and a price-to-earnings ratio of -4.23.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.09. On average, research analysts predict that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new stake in Rapport Therapeutics in the fourth quarter valued at $34,000. Deutsche Bank AG acquired a new stake in Rapport Therapeutics in the fourth quarter valued at $41,000. Virtus ETF Advisers LLC acquired a new stake in Rapport Therapeutics in the fourth quarter valued at $66,000. Corebridge Financial Inc. increased its holdings in Rapport Therapeutics by 79.1% in the first quarter. Corebridge Financial Inc. now owns 8,271 shares of the company's stock valued at $83,000 after purchasing an additional 3,653 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in Rapport Therapeutics by 38.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock valued at $86,000 after purchasing an additional 1,352 shares during the period.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
